Browse TNFSF13

Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. Plays a role in the regulation of tumor cell growth. May be involved in monocyte/macrophage-mediated immunological processes.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006310 DNA recombination
GO:0010608 posttranscriptional regulation of gene expression
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0019724 B cell mediated immunity
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0042113 B cell activation
GO:0043487 regulation of RNA stability
GO:0043488 regulation of mRNA stability
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045830 positive regulation of isotype switching
GO:0045911 positive regulation of DNA recombination
GO:0048290 isotype switching to IgA isotypes
GO:0048296 regulation of isotype switching to IgA isotypes
GO:0048298 positive regulation of isotype switching to IgA isotypes
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0071356 cellular response to tumor necrosis factor
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-74160: Gene Expression
R-HSA-450520: HuR (ELAVL1) binds and stabilizes mRNA
R-HSA-168256: Immune System
R-HSA-450531: Regulation of mRNA stability by proteins that bind AU-rich elements
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFSF13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFSF13 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27127303Plasma Cell MyelomaInhibit immunityAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
27364554Melanoma; Lung carcinomaPromote immunity (T cell function)Here we show that activin A triggers SMAD2 and ERK1/2 pathways in dendritic cells (DC) expressing type I and II activin receptors, and upregulates production of the TNFα family cytokines BAFF (TALL-1, TNFSF13B) and APRIL (TALL-2, TNFSF13A), which is blocked by SMAD2 and ERK1/2 inhibitors, respectively. BAFF and APRIL derived from activin A-treated DCs upregulate proliferation and survival of T cells expressing the corresponding receptors, BAFF-R and TACI.
16880256Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Inhibit immunityIn this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions.
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFSF13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFSF13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0370.899
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1820.921
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0720.956
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5250.192
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1220.947
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0410.68
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.010.976
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3810.578
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5530.518
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0770.552
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8870.761
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1020.431
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFSF13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFSF13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFSF13
Nametumor necrosis factor (ligand) superfamily, member 13
Aliases CD256; TALL-2; TALL2; TRDL-1; UNQ383/PRO715; ZTNF2; TNF- and APOL-related leukocyte expressed ligand 2; a pr ......
Chromosomal Location17p13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFSF13 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.